Oncobiologics (OTLK) Competitors $2.68 +0.27 (+11.20%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.72 +0.03 (+1.31%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. ZYBT, ADCT, FULC, ABEO, CAPR, TNXP, CTMX, INBX, FDMT, and AMRNShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Tonix Pharmaceuticals (TNXP), CytomX Therapeutics (CTMX), Inhibrx Biosciences (INBX), 4D Molecular Therapeutics (FDMT), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Zhengye Biotechnology ADC Therapeutics Fulcrum Therapeutics Abeona Therapeutics Capricor Therapeutics Tonix Pharmaceuticals CytomX Therapeutics Inhibrx Biosciences 4D Molecular Therapeutics Amarin Zhengye Biotechnology (NASDAQ:ZYBT) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Which has preferable earnings and valuation, ZYBT or OTLK? Zhengye Biotechnology has higher revenue and earnings than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$25.53M12.90$1.55MN/AN/AOncobiologics$1.51M59.76-$75.37M-$0.57-4.70 Is ZYBT or OTLK more profitable? Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Oncobiologics N/A N/A -332.30% Do analysts recommend ZYBT or OTLK? Oncobiologics has a consensus target price of $9.60, indicating a potential upside of 258.21%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts clearly believe Oncobiologics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals & insiders believe in ZYBT or OTLK? 11.2% of Oncobiologics shares are held by institutional investors. 4.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor ZYBT or OTLK? In the previous week, Oncobiologics had 9 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 15 mentions for Oncobiologics and 6 mentions for Zhengye Biotechnology. Oncobiologics' average media sentiment score of 0.90 beat Zhengye Biotechnology's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOncobiologics beats Zhengye Biotechnology on 8 of the 11 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.90M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-4.7020.8831.1026.04Price / Sales59.76348.74435.03103.40Price / CashN/A43.1937.7358.48Price / Book-3.198.129.536.61Net Income-$75.37M-$54.72M$3.26B$265.56M7 Day Performance14.53%2.63%2.10%1.97%1 Month Performance28.85%2.78%2.82%-0.36%1 Year Performance-64.41%11.01%30.56%19.03% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.1504 of 5 stars$2.68+11.2%$9.60+258.2%-62.6%$80.90M$1.51M-4.7020News CoverageAnalyst RevisionGap UpHigh Trading VolumeZYBTZhengye BiotechnologyN/A$7.84+4.4%N/AN/A$369.78M$186.36M0.00278News CoverageGap DownADCTADC Therapeutics1.9924 of 5 stars$3.24+3.5%$7.75+139.2%+12.2%$364.50M$70.84M-2.06310High Trading VolumeFULCFulcrum Therapeutics0.9836 of 5 stars$6.64-2.6%$7.57+14.0%-21.7%$359.16M$80M-5.44100ABEOAbeona Therapeutics4.4435 of 5 stars$6.91-3.1%$19.50+182.2%+41.2%$354.35M$3.50M9.8790News CoverageAnalyst RevisionCAPRCapricor Therapeutics3.076 of 5 stars$7.70-3.3%$22.56+192.9%+55.0%$352.04M$22.27M-4.70101Trending NewsTNXPTonix Pharmaceuticals3.1336 of 5 stars$40.07-22.0%$70.00+74.7%+15.0%$351.25M$9.83M-1.0250High Trading VolumeCTMXCytomX Therapeutics4.1016 of 5 stars$2.12+11.0%$5.75+171.2%+78.2%$349.61M$138.10M3.79170High Trading VolumeINBXInhibrx Biosciences1.6841 of 5 stars$23.87+2.3%N/A+92.5%$345.64M$200K-2.26166Analyst ForecastShort Interest ↓FDMT4D Molecular Therapeutics2.0835 of 5 stars$7.27+0.1%$30.40+318.2%-51.0%$339.51M$40K-2.06120AMRNAmarin0.2855 of 5 stars$16.17+3.3%$12.00-25.8%+29.9%$334.88M$228.61M-4.41360 Related Companies and Tools Related Companies Zhengye Biotechnology Competitors ADC Therapeutics Competitors Fulcrum Therapeutics Competitors Abeona Therapeutics Competitors Capricor Therapeutics Competitors Tonix Pharmaceuticals Competitors CytomX Therapeutics Competitors Inhibrx Biosciences Competitors 4D Molecular Therapeutics Competitors Amarin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access